



**Jubilant Pharmova Limited**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
www.jubilantpharmova.com

**PRESS RELEASE**

## **Jubilant Biosys Limited to add Drug Discovery & Preclinical Development capabilities in Biologics and Antibody Drug Conjugate**

**Noida, October 09, 2024:** Jubilant Biosys Innovative Research Services Pte Limited, Singapore ('JBIRSPL'), subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited and Pierre Fabre SA are entering in a strategic partnership. Pursuant to this, JBIRSPL would acquire 80% equity capital in Jasmin (new company incorporated in France, as a Société par Actions Simplifiée (SAS), 100% owned by Pierre Fabre). Jasmin shall acquire Pierre Fabre's R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France upon closing of the transaction.

This strategic partnership will enable Jubilant Biosys Limited to expand its footprint in Europe in areas like Biologics (mAbs) and Antibody Drug Conjugate (ADC), in addition to its existing services including integrated drug discovery services from India.

Speaking on the announcement, **Giuliano Perfetti, CEO & Managing Director of Jubilant Biosys Limited** said, *"We are excited to embark on this new strategic partnership with Pierre Fabre. The facility in Saint Julien will serve as our European Centre of Excellence for Biologics and ADCs, located in the heart of Europe. This will enhance our footprint and collaboration with both biotech and large pharma companies in Europe and the USA. By combining the scientific expertise in Biologics and ADCs at our Saint Julien site with the capabilities of 1,200 scientists at our Centres of Excellence for Drug Discovery, Chemistry and CDMO in India, we can develop a unique delivery model tailored to our customers' needs, driving our company's growth. With this strategic move, Jubilant Biosys continues to strengthen its position as a preferred "CRDMO Partner in Science," committed to delivering innovative solutions to our customers."*

### **About Jubilant Biosys Limited**

Jubilant Biosys Limited provides drug discovery and contract development and manufacturing services to global pharmaceutical and biotech companies. The service offering includes drug discovery services, mg to Kilo, non-GMP and GMP scale up of novel compounds, intermediates and NCEs. The business operates from Bengaluru, Noida and Greater Noida in India, offering integrated and functional drug discovery and development services to global innovators.

Jubilant Biosys Limited has demonstrated expertise in functional services in chemistry including computational, medicinal/ synthetic chemistry, PR&D and GMP scale-up capabilities up to phase II. Services in biology include structural biology, in-vitro biology, DMPK, in-vivo pharmacology and Toxicology. Further, Jubilant Biosys Limited has integrated discovery expertise with a track record of working on over 85 programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases.





## About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with a global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. In the Radiopharma business, the Company is involved in the manufacturing and supply of Radiopharmaceuticals with a network of 46 radiopharmacies in the US. The Company's Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the US and in some other markets such as Canada, Europe and Australia. Jubilant through its CDMO Sterile Injectables business offers manufacturing services including sterile fill and finish injectables (both liquid and lyophilization), full-service ophthalmic offer (liquids, ointments & creams) and ampoules. The CRDMO business of the Company includes the Drug Discovery Services business that provides contract research and development services through two world class research centers in Bengaluru and Noida in India and the CDMO-API business that is involved in the manufacturing of Active Pharmaceutical Ingredients. Jubilant Therapeutics is involved in the Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. The Company operates multiple manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a 'Partner of Choice' by leading pharmaceuticals companies globally.

### For more information, please contact:

#### For Investors

##### **Pankaj Dhawan**

Phone: +91 120 436 1105

E-mail: [Pankaj.dhawan@jubl.com](mailto:Pankaj.dhawan@jubl.com)

##### **Siddharth Rangnekar**

CDR India

Phone: +91 97699 19966

E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

#### For Media

##### **Sandipan Ghatak**

Phone: +91-120 436 1026

E-mail: [sandipan.ghatak@jubl.com](mailto:sandipan.ghatak@jubl.com)

##### **Ryan Marshall**

Madison Public Relations

Phone: +91 9810047944

E-mail: [ryan.marshall@madisonpr.in](mailto:ryan.marshall@madisonpr.in)

### Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.